Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesLoans and Notes ReceivablesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Northwest Biotherapeutics (NWBO) Other Gross PP&E Adjustments (2016 - 2025)

Northwest Biotherapeutics' Other Gross PP&E Adjustments history spans 16 years, with the latest figure at -$20.4 million for Q4 2025.

  • Quarterly results put Other Gross PP&E Adjustments at -$20.4 million for Q4 2025, down 514.08% from a year ago — trailing twelve months through Dec 2025 was -$20.4 million (down 514.08% YoY), and the annual figure for FY2025 was -$20.4 million, down 514.08%.
  • Other Gross PP&E Adjustments for Q4 2025 was -$20.4 million at Northwest Biotherapeutics, down from $14.6 million in the prior quarter.
  • In the past five years, Other Gross PP&E Adjustments ranged from a high of $18.1 million in Q1 2025 to a low of -$20.4 million in Q4 2025.
  • The 5-year median for Other Gross PP&E Adjustments is -$3.9 million (2022), against an average of $82550.0.
  • The sharpest move saw Other Gross PP&E Adjustments soared 1285.92% in 2024, then crashed 514.08% in 2025.
  • Year by year, Other Gross PP&E Adjustments stood at $11.2 million in 2021, then crashed by 134.66% to -$3.9 million in 2022, then surged by 449.76% to $13.6 million in 2023, then tumbled by 124.48% to -$3.3 million in 2024, then crashed by 514.08% to -$20.4 million in 2025.
  • According to Business Quant data, Other Gross PP&E Adjustments over the past three periods came in at -$20.4 million, $14.6 million, and -$837000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.